Bluish pigmentation of the nails in AIDS patients. Possibly an adverse effect of Zidovudine?
González Lahoz, J.M.; García Aguado, C.; Martínez Fernández, R.; Laguna Cuesta, F.
Revista Clinica Espanola 183(5): 278-279
1988
ISSN/ISBN: 0014-2565 PMID: 2981033 Document Number: 308595
Document emailed within 1 workday
Related Documents
Dolin, R.; Amato, D.A.; Fischl, M.A.; Pettinelli, C.; Beltangady, M.; Liou, S.H.; Brown, M.J.; Cross, A.P.; Hirsch, M.S.; Hardy, W.D. 1995: Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group Archives of Internal Medicine 155(9): 961-974Molina, M.; Ortega, G.; Valiente, B. 1996: Progressive idiopathic pigmentation of the nails and lips of a woman Revista Clinica Espanola 196(11): 791-792
Fischl, M.A.; Richman, D.D.; Causey, D.M.; Grieco, M.H.; Bryson, Y.; Mildvan, D.; Laskin, O.L.; Groopman, J.E.; Volberding, P.A.; Schooley, R.T. 1989: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group JAMA 262(17): 2405-2410
Lundgren, J.D.; Phillips, A.N.; Pedersen, C.; Clumeck, N.; Gatell, J.M.; Johnson, A.M.; Ledergerber, B.; Vella, S.; Nielsen, J.O. 1994: Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group JAMA 271(14): 1088-1092
Creagh-Kirk, T.; Doi, P.; Andrews, E.; Nusinoff-Lehrman, S.; Tilson, H.; Hoth, D.; Barry, D.W. 1988: Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program JAMA 260(20): 3009-3015
Steinberg, J.P.; Spear, J.B.; Murphy, R.L.; Wallemark, C.B.; Benson, C.A.; Kessler, H.A.; Pottage, J.C.; Phair, J.P. 1989: Predictors of outcome in AIDS patients receiving zidovudine Journal of Acquired Immune Deficiency Syndromes 2(3): 229-234
Vago, L.; Castagna, A.; Lazzarin, A.; Trabattoni, G.; Cinque, P.; Costanzi, G. 1993: Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine Journal of Acquired Immune Deficiency Syndromes 6(1): 42-45
Claasen, J.N. 1988: Decrease in human immunodeficiency virus antigen titer in the cerebrospinal fluid during treatment of AIDS patients with zidovudine Nederlands Tijdschrift Voor Geneeskunde 132(46): 2122-2123
Garavelli, P.L. 1992: Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report Haematologica 77(3): 293-294
Krown, S.E.; Gold, J.W.; Niedzwiecki, D.; Bundow, D.; Flomenberg, N.; Gansbacher, B.; Brew, B.J. 1990: Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Annals of Internal Medicine 112(11): 812-821
Hochster, H.; Dieterich, D.; Bozzette, S.; Reichman, R.C.; Connor, J.D.; Liebes, L.; Sonke, R.L.; Spector, S.A.; Valentine, F.; Pettinelli, C. 1990: Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study Annals of Internal Medicine 113(2): 111-117
Katlama, C.; Ingrand, D.; Loveday, C.; Clumeck, N.; Mallolas, J.; Staszewski, S.; Johnson, M.; Hill, A.M.; Pearce, G.; McDade, H. 1996: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. a randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group JAMA 276(2): 118-125
Gartland, M. 2001: AVANTi 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients Antiviral Therapy 6(2): 127-134
Price, R.W.; Yiannoutsos, C.T.; Clifford, D.B.; Zaborski, L.; Tselis, A.; Sidtis, J.J.; Cohen, B.; Hall, C.D.; Erice, A.; Henry, K. 1999: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team Aids 13(13): 1677-1685
Shenton, J. 1992: HIV, AIDS, and zidovudine Lancet 339(8796): 806
Pomeroy, C. 1993: Zidovudine therapy of HIV-associated thrombocytopenia: from MAIDS to AIDS Journal of Laboratory and Clinical Medicine 121(4): 536-538
Scarsella, A.; Coodley, G.; Shalit, P.; Anderson, R.; Fisher, R.L.; Liao, Q.; Ross, L.L.; Hernandez, J.E. 2002: Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience Advances in Therapy 19(1): 1-8
Balslev, U.; Nielsen, T.L. 1992: Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients Danish Medical Bulletin 39(4): 366-368
Mays, D.C.; Dixon, K.F.; Balboa, A.; Pawluk, L.J.; Bauer, M.R.; Nawoot, S.; Gerber, N. 1991: A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats Journal of Pharmacology and Experimental Therapeutics 259(3): 1261-1270
Shintaku, M.; Nasu, K.; Shimizu, T. 1993: Fulminant hepatic failure in an AIDS patient: possible zidovudine-induced hepatotoxicity American Journal of Gastroenterology 88(3): 464-466